What is HC Wainwright’s Forecast for Metagenomi Q1 Earnings?

Metagenomi, Inc. (NASDAQ:MGX) – Stock analysts at HC Wainwright upped their Q1 2025 earnings estimates for shares of Metagenomi in a research report issued to clients and investors on Thursday, April 3rd. HC Wainwright analyst M. Kapoor now forecasts that the company will earn ($0.47) per share for the quarter, up from their previous estimate of ($0.56). HC Wainwright has a “Buy” rating and a $7.00 price target on the stock. The consensus estimate for Metagenomi’s current full-year earnings is ($2.46) per share. HC Wainwright also issued estimates for Metagenomi’s Q2 2025 earnings at ($0.51) EPS, Q3 2025 earnings at ($0.54) EPS, Q4 2025 earnings at ($0.58) EPS and FY2025 earnings at ($2.10) EPS.

Metagenomi (NASDAQ:MGX) last posted its quarterly earnings results on Monday, March 17th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.01). Metagenomi had a negative net margin of 134.27% and a negative return on equity of 43.23%. The company had revenue of $9.61 million during the quarter, compared to analysts’ expectations of $13.18 million. During the same quarter last year, the company earned ($20.05) earnings per share.

Separately, Wells Fargo & Company lowered their price target on shares of Metagenomi from $25.00 to $20.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 18th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $13.00.

Metagenomi Stock Performance

NASDAQ MGX opened at $1.43 on Monday. The stock’s fifty day moving average is $2.07 and its two-hundred day moving average is $2.37. The firm has a market capitalization of $53.46 million, a P/E ratio of -0.55 and a beta of -0.27. Metagenomi has a fifty-two week low of $1.23 and a fifty-two week high of $10.50.

Institutional Trading of Metagenomi

Several institutional investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets boosted its stake in shares of Metagenomi by 130.9% in the third quarter. BNP Paribas Financial Markets now owns 12,799 shares of the company’s stock valued at $28,000 after purchasing an additional 7,256 shares during the period. Verition Fund Management LLC acquired a new stake in Metagenomi during the 3rd quarter worth approximately $82,000. Geode Capital Management LLC lifted its holdings in Metagenomi by 105.8% during the 3rd quarter. Geode Capital Management LLC now owns 338,031 shares of the company’s stock worth $734,000 after buying an additional 173,796 shares in the last quarter. Peapod Lane Capital LLC purchased a new position in Metagenomi in the 4th quarter valued at approximately $1,268,000. Finally, Rhumbline Advisers grew its stake in shares of Metagenomi by 123.3% in the fourth quarter. Rhumbline Advisers now owns 11,998 shares of the company’s stock worth $43,000 after acquiring an additional 6,626 shares in the last quarter.

About Metagenomi

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.